Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL IN PLASTIC CONTAINER versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL IN PLASTIC CONTAINER versus CLOXAPEN.
BACTOCILL IN PLASTIC CONTAINER vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
1-2 g intravenously every 4 hours.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic